Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation

References

• KiberstisPATravisJCelebrating a glass half-fullScience20063121157
   Web of Science ®Google Scholar
• MurphyKMTopelRHThe value of health and longevityJ Polit Econ2006114871904
   Web of Science ®Google Scholar
• US National Institues of HealthPresident’s Cancer Panel2007–2008 annual report Available from: http://deainfo.nci.nih.gov/advisory/pcp/pcp.htmAccessed April 23, 2012
   Google Scholar
• MorganGWardRBartonMThe contribution of cytotoxic chemotherapy to 5-year survival in adult malignanciesClin Oncol (R Coll Radiol)20041654956015630849
   PubMed Web of Science ®Google Scholar
• DeVitaVTJrLawrenceTSRosenbergSADePinhoRAWeinbergRADeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology9th edNew YorkLippincott2011
   Google Scholar
• CoventryBJAshdownMLQuinnMAMarkovicSNYatomi-ClarkeSLRobinsonAPCRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?J Transl Med2009710219948067
   PubMed Web of Science ®Google Scholar
• AshdownMLCoventryBJA Matter of TimeAustralasian Science520101820
   Google Scholar
• CoventryBJImmuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanomaJ Cancer Ther20101205213
   Google Scholar
• LeontovichAADroncaRSSumanVJFluctuation of systemic immunity in melanoma and implications for timing of therapyFront Biosci (Elite Ed)2012495897522201928
   PubMedGoogle Scholar
• LeslieM‘Danger signals’ from dying cells jolt immune system into actionScience Epub February 9, 2012
   Google Scholar
• LugadeAAMoranJPGerberSARoseRCFrelingerJGLordEMLocal radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumorJ Immunol2005174127516752315944250
   PubMed Web of Science ®Google Scholar
• SchaueDRatikanJAIwamotoKSMcBrideWHMaximizing tumor immunity with fractionated radiationInt J Radiat Oncol Biol Phys Epub December 28, 2011
   Web of Science ®Google Scholar
• TabachnykMDistelLVBüttnerMRadiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancerOral Oncol Epub February 20, 2012
   Web of Science ®Google Scholar
• OlivierKRSchildSEMorrisCGBrownPDMarkovicSNA higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanomaCancer20071101791179517721993
   PubMed Web of Science ®Google Scholar
• MortonRTreatment of Metastatic MelanomaCroatiaIntech Publishers2011
   Google Scholar
• PetersenRPHanishSIHaneyJCJ Thorac Cardiovasc Surg2007133110411017198792
   PubMed Web of Science ®Google Scholar
• EssnerRLeeJHWanekLAItakuraHMortonDLContemporary surgical treatment of advanced-stage melanomaArch Surg20041399961966 discussion 966–96715381613
   PubMedGoogle Scholar
• BalchCHoughtonASoberASoongSCutaneous Melanoma4th edSt LouisQuality Medical Publishing, Inc2003
   Google Scholar
• OllilaDWHsuehECSternSLMortonDLMetastasectomy for recurrent stage IV melanomaJ Surg Oncol199971420921310440757
   PubMed Web of Science ®Google Scholar
• BarthAWanekLAMortonDLPrognostic factors in 1,521 melanoma patients with distant metastasesJ Am Coll Surg199518131932017670677
   PubMed Web of Science ®Google Scholar
• WongJHEuhusDMMortonDLSurgical resection for metastatic melanoma to the lungArch Surg19881239109110953415459
   PubMedGoogle Scholar
• LoiSde AzambujaEPuglianoLSotiriouCPiccartMJHER2- overexpressing breast cancer: time for the cure with less chemotherapy?Curr Opin Oncol201123654755821918439
   PubMed Web of Science ®Google Scholar
• MurphyCGFornierMHER2-positive breast cancer: beyond trastuzumabOncology (Williston Park)201024541041520480738
   PubMed Web of Science ®Google Scholar
• AbramsonVArteagaCLNew strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs availableClin Cancer Res201117595295821248299
   PubMed Web of Science ®Google Scholar
• GrantSLHammacherADouglasAMAn unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cellsOncogene (England)2002213460474
   Web of Science ®Google Scholar
• HalabanRZhangWBacchiocchiAPLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cellsPigment Cell Melanoma Res201123219020020149136
   PubMed Web of Science ®Google Scholar
• ErnstoffMSBeen there, not done that – melanoma in the age of molecular therapyN Engl J Med2011364262547254821639809
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med201036380981920818844
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• RibasAFlahertyKTBRAF targeted therapy changes the treatment paradigm in melanomaNat Rev Clin Oncol20118742643321606968
   PubMed Web of Science ®Google Scholar
• SosmanJAKimKBSchuchterLSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibN Engl J Med2012366870771422356324
   PubMed Web of Science ®Google Scholar
• HatzivassiliouGSongKYenIRAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature2010464728743143520130576
   PubMed Web of Science ®Google Scholar
• GrivasPDRedmanBGImmunotherapy of kidney cancerCurr Clin Pharmacol20116315116321827390
   PubMedGoogle Scholar
• KnoechelBLohrJKahnEBluestoneJAAbbasAKSequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigenJ Exp Med2005202101375138616287710
   PubMed Web of Science ®Google Scholar
• McNallyAHillGRSparwasserTThomasRSteptoeRJCD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasisProc Natl Acad Sci U S A2011108187529753421502514
   PubMed Web of Science ®Google Scholar
• SojkaDKHughsonASukiennickiTLFowellDJEarly kinetic window of target T cell susceptibility to CD25+ regulatory T cell activityJ Immunol2005175117274728016301632
   PubMed Web of Science ®Google Scholar
• AhmadzadehMRosenbergSAIL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patientsBlood200610762409241416304057
   PubMed Web of Science ®Google Scholar
• CoventryBJAshdownMLMarkovicSNImmune therapies for cancer: bimodality – the blind spot to clinical efficacy – lost in translationJ Immunother2011349717
   Google Scholar
• BitonJBoissierMCBessisNTNFα: activator or inhibitor of regulatory T cells?Joint Bone Spine201279211912322209316
   PubMed Web of Science ®Google Scholar
• FilippiCMJuedesAEOldhamJETransforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunityDiabetes200857102684269218689691
   PubMed Web of Science ®Google Scholar
• O’ConnorWJrKamanakaMBoothCJA protective function for interleukin 17 in T cell-mediated intestinal inflammationNat Immunol200910660360919448631
   PubMed Web of Science ®Google Scholar
• ChenXOppenheimJJTNF-alpha: an activator of CD4+FoxP3+ TNFR2+ regulatory T cellsCurr Dir Autoimmun20101111913420173391
   PubMedGoogle Scholar
• EvangelidouMTsevelekiVVamvakasSSProbertLTNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responsesImmunol Cell Biol201088558659520212506
   PubMed Web of Science ®Google Scholar
• ChenXOppenheimJJContrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunityFEBS Lett2011585233611361821513711
   PubMed Web of Science ®Google Scholar
• ComerfordIBuntingMFenixKAn immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune diseaseBioessays201032121067107620954179
   PubMed Web of Science ®Google Scholar
• MummJBEmmerichJZhangXIL-10 elicits IFNγ-dependent tumor immune surveillanceCancer Cell201120678179622172723
   PubMed Web of Science ®Google Scholar
• A delicate balance: tweaking IL-2 immunotherapyNat Med201218220820922310686
   PubMed Web of Science ®Google Scholar
• PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
   PubMed Web of Science ®Google Scholar
• JainNNguyenHChambersCKangJDual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunityProc Natl Acad Sci U S A20111074152420080649
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• QureshiOSZhengYNakamuraKTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4Science201129:332602960060321474713
   PubMed Web of Science ®Google Scholar
• CoventryBHeinzelSCD1a in human cancers: a new role for an old moleculeTrends Immunol200425524224815099564
   PubMed Web of Science ®Google Scholar
• XuHCaoXDendritic cell vaccines in cancer immunotherapy: from biology to translational medicineFront Med20115432333222198743
   PubMedGoogle Scholar
• PandolfiFCianciRPagliariDThe immune response to tumors as a tool toward immunotherapyClin Dev Immunol2011201189470422190975
   PubMed Web of Science ®Google Scholar
• TuyaertsSDendritic cell therapy for oncology roundtable conferenceJ Immune Based Ther Vaccines201191121226916
   PubMedGoogle Scholar
• NakaiNHartmannGKishimotoSKatohNDendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parametersPigment Cell Melanoma Res201023560761920579307
   PubMed Web of Science ®Google Scholar
• TumaRSLarge trials, small gains: is change on the way?J Natl Cancer Inst20101021612161217122320693460
   PubMedGoogle Scholar
• GlundeKBhujwallaZMMetabolic tumor imaging using magnetic resonance spectroscopySemin Oncol2011381264121362514
   PubMed Web of Science ®Google Scholar
• GlundeKJiangLMoestueSAGribbestadISMRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancerNMR Biomed201124667369021793073
   PubMed Web of Science ®Google Scholar